BridgeBio Q3 2025: $120.7M revenue, Attruby launch accelerating; positive Phase 3 data for BBP-418 and encaleret

BridgeBio Pharma, Inc.

2025-Q3 EPS reported -$2.79 vs consensus -$0.91 ▼ miss (-207.8%)

Total revenue $120.7M (Q3 2024: $2.7M), driven by $108.1M Attruby net product revenue.
Net loss $182.7M ($0.95/sh) vs $162.0M ($0.86/sh) in prior year; cash $645.9M.
Attruby: 5,259 prescriptions written by 1,355 prescribers since Nov 2024 approval.
BBP-418 Phase 3 met endpoints: glycosylated αDG increased 1.8x (p<0.0001); NDA filing planned 1H 2026.
Encaleret Phase 3 met primary endpoint: 76% achieved target calcium vs 4% on conventional (p<0.0001); NDA in 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.